AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$GMED

TOBIN JAMES R sold $2.2M of GMED

TOBIN JAMES R sold 30,000 shares of GLOBUS MEDICAL INC (GMED) at $74.58 ($2.24M total) on 2026-09-15.

Original reporting
SEC EDGAR · TOBIN JAMES R
Published Sep 16, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GMED
Bearish
medium confidence
Mentioned
$GMED
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GMEDBearishLow
01

Why it matters

The sale represents a material insider transaction that could influence investor sentiment.

02

Market read

First-report insider sale; may affect short-term trading decisions on GMED.

03

What to watch

Potential tax-driven sale or portfolio rebalancing; not necessarily a bearish signal.

Relevance 6/10Novelty 6/10Timing: post-market 2026-09-15

Background

Form 4 filing disclosed a director's complete exit from Globus Medical shares.

Company-level read

Ticker impact

$GMEDBearishMedium confidence
Context

Director Tobin James R sold 30,000 shares for $2.24M, reducing his stake to zero.

Expected impact

Short-term downward pressure expected.

Evidence & confidence

Large insider sale ($2.2M) by a director is material; market may interpret as negative.

Market effects

Sector

Minimal impact on medical device sector; may prompt scrutiny of other insider holdings.

Regional

US market only; no broader regional effect.

Global

Limited to investors tracking Globus Medical.

Counterpoint

What could challenge this read

Insider sell could be unrelated to company fundamentals; price may remain stable.

Key entities

  • Company
    Globus Medical Inc.

    Medical device manufacturer listed on NASDAQ (GMED).

  • Individual
    Tobin James R

    Director of Globus Medical who sold his entire shareholding.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GMED insider trading history →

Related articles

SEP 10
$GMEDMedAI 8/10

Audubon's Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union

Globus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.

biobuzz.io2 min
SEP 5
$GMEDMedAI 8/10

What Does Globus Medical (GMED) CE Mark Approval Mean For Its Europe Launch?

Globus Medical (GMED) received CE Mark approval for its Excelsius3D imaging system, allowing its commercial launch in the EU and UK. The approval expands the company's Excelsius platform into new markets, supporting advanced surgical procedures. Globus Medical, with a market cap of $10.5b, aims to integrate robotics, imaging, and implants for higher margins in spine and orthopaedic care.

simplywall.st3 min
SEP 4
$GMEDMedAI 8/10

Globus Medical wins CE mark for Excelsius3D imaging system

Globus Medical (GMED) received CE mark for its Excelsius3D imaging system for spine and cranial procedures, enabling EU/UK commercialization. The system combines 3D CT, 2D fluoroscopy, and digital radiography, integrating with the ExcelsiusGPS robotic navigation system. According to the company, this expands its Excelsius ecosystem in Europe.

massdevice.com1 min
SEP 4
$GMEDHighAI 9/10

Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System

Globus Medical (GMED) received CE marking for its Excelsius3D imaging system, allowing commercial launch in the EU and UK. The system is part of the company's imaging and navigation platform for spine and orthopedic procedures. Globus Medical has a market cap of approximately $10.8 billion. The approval supports the company's strategy in surgical imaging and guidance platforms, potentially contributing to earnings and margin expansion.

finance.yahoo.com2 min